Agios Pharmaceuticals, Inc. (AGIO)
Automate Your Wheel Strategy on AGIO
With Tiblio's Option Bot, you can configure your own wheel strategy including AGIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AGIO
- Rev/Share 0.6445
- Book/Share 25.5229
- PB 1.2573
- Debt/Equity 0.0361
- CurrentRatio 18.497
- ROIC -0.2716
- MktCap 1858498768.0
- FreeCF/Share -7.0271
- PFCF -4.6028
- PE 2.7686
- Debt/Assets 0.034
- DivYield 0
- ROE 0.5031
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AGIO | H.C. Wainwright | -- | Buy | -- | $58 | Feb. 24, 2025 |
| Initiation | AGIO | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
| Resumed | AGIO | Raymond James | -- | Outperform | -- | $51 | Oct. 10, 2024 |
| Downgrade | AGIO | Leerink Partners | Outperform | Market Perform | $60 | $56 | Sept. 27, 2024 |
News
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.
Read More
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET.
Read More
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call.
Read More
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Read More
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- …
Read More
New Strong Sell Stocks for April 3rd
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Negative
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Read More
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
Read More
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 …
Read More
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Negative
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago.
Read More
About Agios Pharmaceuticals, Inc. (AGIO)
- IPO Date 2013-07-24
- Website https://www.agios.com
- Industry Biotechnology
- CEO Mr. Brian M. Goff M.B.A.
- Employees 486